the present invention will now be described more specifically with reference to the following embodiments . it is to be noted that the following descriptions of preferred embodiments of this invention are presented herein for purpose of illustration and description only ; it is not intended to be exhaustive or to be limited to the precise form disclosed . in order to accomplish the purpose of the present invention , the technical schemes of the present invention are particularly provided as follows . a pharmaceutical composition with multi - target and post - receptor mechanism for treating depression is disclosed in the present invention , and the pharmaceutical composition is manufactured by including the raw materials of ginsenoside rg1 and rb1 , and glycyrrhizic acid ( or glycyrrhetinic acid ). the pharmaceutical composition with multi - target and post - receptor mechanism of the present invention for treating depression is manufactured by including the raw materials of ginsenoside rg1 and rb1 , and glycyrrhizic acid ( or glycyrrhetinic acid ). the pharmaceutical composition of the present invention is manufactured from the raw materials having a total of 2 ˜ 26 parts by weight of ginsenoside rg1 and rb1 , and 3 ˜ 48 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ). the pharmaceutical composition of the present invention is manufactured by including the raw materials having a total of 4 ˜ 13 parts by weight of ginsenoside rg1 and rb1 , and 5 ˜ 16 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ). the pharmaceutical composition with multi - target and post - receptor mechanism for treating depression of the present invention is manufactured by including the raw materials of ginsenoside rg1 and rb1 , glycyrrhizic acid ( or glycyrrhetinic acid ) and jujuba camp . the pharmaceutical composition of the present invention is manufactured by including the raw materials having a total of 2 ˜ 26 parts by weight of ginsenoside rg1 and rb1 , 3 ˜ 48 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ) and 0 . 002 ˜ 0 . 5 parts by weight of jujuba camp . the pharmaceutical composition of the present invention is manufactured by including the raw materials having a total of 4 ˜ 13 parts by weight of ginsenoside rg1 and rb1 , 5 ˜ 16 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ) and 0 . 01 ˜ 0 . 1 parts by weight of jujuba camp . the pharmaceutical composition of the present invention can include the pharmacologically acceptable carriers or additives . the pharmaceutical composition can be manufactured as a dosage form , and the dosage form is selected from one of a tablet , a capsule , a powder , a pill , a dust , a solution , a microcapsule , a suspension , an emulsion , a particle , a dropping pill , a roll and a pharmacologically oral pharmaceutical dosage form . the pharmaceutical composition of the present invention can be manufactured as pharmaceuticals , health food and nutrient supplements for treating depression . in order to accomplish the purpose of the present invention , the preparation methods of the pharmaceutical composition are described as follows . the pharmaceutical composition with multi - target and post - receptor mechanism of the present invention for treating depression is manufactured from one extract having ginsenoside rg1 and rb1 extracted from ginseng , and another extract having glycyrrhizic acid extracted from liquorice as the raw materials . in addition , the aforementioned pharmaceutical composition is manufactured by directly using the prepared raw materials having ginsenoside rg1 and rb1 , and glycyrrhizic acid ( or glycyrrhetinic acid ). the pharmaceutical composition of the present invention is manufactured from the raw materials having a total of 2 ˜ 26 parts by weight of ginsenoside rg1 and rb1 , and 3 ˜ 48 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ). the pharmaceutical composition of the present invention is manufactured by including the raw materials having a total of 4 ˜ 13 parts by weight of ginsenoside rg1 and rb1 , and 5 ˜ 16 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ). the pharmaceutical composition with multi - target and post - receptor mechanism of the present invention for treating depression is manufactured from one extract having ginsenoside rg1 and rb1 extracted from ginseng , another extract having glycyrrhizic acid extracted from liquorice , and the other extract having jujuba camp extracted from jujuba as the raw materials . in addition , the aforementioned pharmaceutical composition is manufactured by directly using the prepared raw materials having ginsenoside rg1 and rb1 , glycyrrhizic acid ( or glycyrrhetinic acid ) and jujuba camp . the pharmaceutical composition of the present invention is manufactured from the raw materials having a total of 2 ˜ 26 parts by weight of ginsenoside rg1 and rb1 , 3 ˜ 48 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ) and 0 . 002 ˜ 0 . 5 parts by weight of jujuba camp . the pharmaceutical composition of the present invention is manufactured from the raw materials having a total of 4 ˜ 13 parts by weight of ginsenoside rg1 and rb1 , 5 ˜ 16 parts by weight of glycyrrhizic acid ( or glycyrrhetinic acid ) and 0 . 01 ˜ 0 . 1 parts by weight of jujuba camp . the pharmaceutical composition of the present invention can include the pharmacologically acceptable carriers or additives . the pharmaceutical composition can be manufactured as a dosage form , and the dosage form is selected from one of a tablet , a capsule , a powder , a pill , a dust , a solution , a microcapsule , a suspension , an emulsion , a particle , a dropping pill , a roll and a pharmacologically oral pharmaceutical dosage form . the pharmaceutical composition of the present invention can be manufactured from the raw materials described in the present invention in accordance with the method of the good manufacturing practice ( gmp ) about the health food . the present invention is further illustrated as follows by combining the figures and the preferred embodiments . please refer to fig1 , which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a first preferred embodiment of the present invention . in fig1 , after 20 kg of ginseng ( step 101 ) is fractured , the fractured ginseng is heated to be extracted by 70 % concentration of the ethanol solution . the extracted ginseng is separated by column chromatography , purified and dried , and 0 . 8 kg of the ginseng extract having 120 g of ginsenoside rg1 and rb1 is obtained ( step 102 ). then , after 10 kg of liquorice ( step 103 ) is fractured , the fractured liquorice is soaked at room temperature for 12 hours . the soaked liquorice is extracted by decoction and alcohol sedimentation , concentrated and dried , and 2 kg of the liquorice extract having 200 g of glycyrrhizic acid is obtained ( step 104 ). afterwards , 150 g of the obtained ginseng extract and 200 g of the obtained liquorice extract are pulverized and mixed , and 350 g of the pharmaceutical composition ( containing 22 . 5 g of ginsenoside rg1 and rb1 , and 20 g of glycyrrhizic acid ) of the example 1 of the present invention is obtained ( step 105 ). please refer to fig2 , which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a second preferred embodiment of the present invention . in fig2 , after the prepared 3 . 96 g of glycyrrhetinic acid having 96 % purity ( step 202 ) and 200 g of the obtained ginseng extract in the embodiment 1 ( step 201 ) are pulverized and mixed , 203 . 96 g of the pharmaceutical composition ( containing 30 g of ginsenoside rg1 and rb1 , and 3 . 8 g of glycyrrhetinic acid ) of the example 2 of the present invention is obtained ( step 203 ). please refer to fig3 , which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a third preferred embodiment of the present invention . in fig3 , after 3 . 4 g of the prepared ginsenoside rg1 having 90 % purity ( step 301 ), 7 . 8 g of the prepared ginsenoside rb1 having 90 % purity ( step 302 ) and 36 . 8 g of glycyrrhizic acid having 90 % purity ( step 303 ) are pulverized and mixed , 48 g of the pharmaceutical composition ( containing 10 g of ginsenoside rg1 and rb1 , and 35 g of glycyrrhizic acid ) of the example 3 of the present invention is obtained ( step 304 ). please refer to fig4 , which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a fourth preferred embodiment of the present invention . in fig4 , 10 kg of jujuba ( step 401 ) is fractured and soaked in water at room temperature . then , the soaked jujuba is extracted by decoction and alcohol sedimentation for obtaining the jujuba extract , which is further absorbed and separated by the ou - 2 and me - 2 macroporous resins sequentially , and dried . thirty ( 30 ) g of the jujuba extract containing 0 . 3 g of jujuba camp is obtained to be the raw material for preparing the pharmaceutical of the present invention ( step 402 ). afterwards , after 150 g of the ginseng extract and 200 g of the liquorice extract obtained in the embodiment 1 are pulverized and mixed with 3 g of the aforementioned jujuba extract , 353 g of the pharmaceutical composition ( containing 22 . 5 g of ginsenoside rg1 and rb1 , 20 g of glycyrrhizic acid and 0 . 03 g of jujuba camp ) of the example of the present invention is obtained ( step 403 ). please refer to fig5 , which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a fifth preferred embodiment of the present invention . in fig5 , after 150 g of the ginseng extract ( step 501 ) and 200 g of the liquorice extract ( step 502 ) obtained in the embodiment 1 respectively are pulverized and mixed with 0 . 5 g of the jujuba extract obtained in the embodiment 4 ( step 503 ), 350 . 5 g of the pharmaceutical composition ( containing 22 . 5 g of ginsenoside rg1 and rb1 , 20 g of glycyrrhizic acid and 0 . 005 g of jujuba camp ) of the example 5 of the present invention is obtained ( step 504 ). please refer to fig6 , which is the flowchart showing a preparation method of a pharmaceutical composition in accordance with a sixth preferred embodiment of the present invention . in fig6 , after 6 . 8 g of the prepared ginsenoside rg1 having 90 % purity ( step 601 ), 15 . 6 g of the prepared ginsenoside rb1 having 90 % purity ( step 602 ), 26 g of glycyrrhetinic acid having 96 % purity ( step 603 ) and 10 g of the jujuba extract obtained in the embodiment 4 ( step 604 ) are pulverized and mixed , 58 . 4 g of the pharmaceutical composition ( containing 20 g of ginsenoside rg1 and rb1 , 25 g of glycyrrhetinic acid and 0 . 1 g of jujuba camp ) of the example 6 of the present invention is obtained ( step 605 ). 1 . 1 experimental animals : icr mice , male , 22 . 0 ± 2 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . 1 . 2 experiment pharmaceuticals : the pharmaceutical of embodiment 1 is provided by beijing wonner biotech . ltd . co ., and paroxetine ( paxil ) is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd . 1 . 4 dose designs : 1 . high dose of embodiment 1 ( 80 mg / kg / d ); 2 . middle dose of embodiment 1 ( 40 mg / kg / d ); and 3 . low dose of embodiment 1 ( 20 mg / kg / d ). 1 . 5 . 1 group division and administration of drug : the mice are grouped randomly , and 10 mice are in each group . 1 . high dose of embodiment 1 ( 80 mg / kg , per oral ( p . o . ), administered for 7 days ); 2 . middle dose of embodiment 1 ( 40 mg / kg , p . o ., administered for 7 days ); 3 . low dose of embodiment 1 ( 20 mg / kg , p . o ., administered for 7 days ); 4 . paroxetine ( 3 mg / kg , p . o ., administered for 7 days ); and 5 . physiological saline ( p . o .). after 1 hour of the last administration of drug , the mouse tail - hanging experiment is proceeded . 1 . 5 . 2 experimental method : the mouse &# 39 ; s tail ( 1 cm to the tail end ) is taped on the wood strip higher than the platform for 5 cm and hung up for 6 minutes . the time of non - movement of the mouse for the last 5 minutes is recorded . 1 . 5 . 3 statistic calculation : the experimental data are represented as x ± sd , and the experimental result is calculated as analysis of variance ( anova ) by spss 11 . 5 statistic software . conclusion : according to the above experiment , it can be found that the high and middle doses of embodiment 1 of the present invention and paroxetine all decrease the time of non - movement after the mouse &# 39 ; s tail is hung up , significantly different in comparison with the physiological group ( control ). therefore , the embodiment 1 of the present invention having anti - experimental depression function can be extrapolated . the influence of embodiment 1 in the resetpine - induced mouse body temperature decrease experiment 2 . 1 experimental animals : icr mice , male , 22 . 0 ± 2 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . 2 . 2 experiment pharmaceuticals : the pharmaceutical of embodiment 1 is provided by beijing wonner biotech . ltd . co ., paroxetine ( paxil ) is the product of thong mei tianjin smith kline pharmaceuticals co . ltd ., and resetpine is the product of guangdong bangmin pharmaceutical co ., ltd . 2 . 4 dose designs : 1 . high dose of embodiment 1 ( 80 mg / kg / d ); 2 . middle dose of embodiment 1 ( 40 mg / kg / d ); and 3 . low dose of embodiment 1 ( 20 mg / kg / d ). 2 . 5 . 1 group division and administration of drug : the mice are grouped randomly , and 10 mice are in each group . 1 . high dose of embodiment 1 ( 80 mg / kg , p . o ., administered for 7 days ); 2 . middle dose of embodiment 1 ( 40 mg / kg , p . o ., administered for 7 days ); 3 . low dose of embodiment 1 ( 20 mg / kg , p . o ., administered for 7 days ); 4 . paroxetine ( 3 mg / kg , p . o ., administered for 7 days ); and 5 . physiological saline ( p . o .). 2 . 5 . 2 experimental method : after 1 hour of the last administration of drug on the eighth day , the mouse &# 39 ; s anal temperature is determined . then 2 mg resetpine per kilogram of the body weight is given by intraperitoneal injection . after 4 hours of injecting resetpine , the mouse &# 39 ; s anal temperature is determined once again . the depth and time of injecting the thermometer to the mouse &# 39 ; s anus are identical in each temperature measurement . 2 . 5 . 3 statistic calculation : the experimental data are represented as x ± sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . conclusion : according to the above experiment , it can be found that the high , middle and low doses of embodiment 1 of the present invention and paroxetine all decrease the reduced body temperature induced by resetpine ; it means that the anti - experimental depression functions of these pharmaceuticals might be related to their effects on the contents of monoamine neurotransmitter . therefore , the embodiment 1 of the present invention having anti - experimental depression function can be extrapolated . 3 . 1 experimental animals : icr mice , male , 22 . 0 ± 2 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . 3 . 2 experiment pharmaceuticals : the pharmaceutical of embodiment 2 is provided by beijing wormer biotech . ltd . co ., and paroxetine ( paxil ) is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd . 3 . 4 dose designs : 1 . high dose of embodiment 2 ( 80 mg / kg / d ); 2 . middle dose of embodiment 2 ( 40 mg / kg / d ); and 3 . low dose of embodiment 2 ( 20 mg / kg / d ). 3 . 5 . 1 group division and administration of drug : the mice are grouped randomly , and 10 mice are in each group . 1 . high dose of embodiment 2 ( 80 mg / kg , p . o ., administered for 7 days ); 2 . middle dose of embodiment 2 ( 40 mg / kg , p . o ., administered for 7 days ); 3 . low dose of embodiment 2 ( 20 mg / kg , p . o ., administered for 7 days ); 4 . paroxetine ( 3 mg / kg , p . o ., administered for 7 days ); and 5 . physiological saline ( p . o .). after 1 hour of the last administration of drug , the mouse tail - hanging experiment is proceeded . 3 . 5 . 2 experimental method : the mouse &# 39 ; s tail ( 1 cm to the tail end ) is taped on the wood strip higher than the platform for 5 cm and hung up for 6 minutes . the time of non - movement of the mouse for the last 5 minutes is recorded . 3 . 5 . 3 statistic calculation : the experimental data are represented as x ± sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . conclusion : according to the above experiment , it can be found that the middle dose of embodiment 2 of the present invention and paroxetine all decrease the time of non - movement after the mouse &# 39 ; s tail is hung up , significantly different in comparison with the physiological group ( control ). therefore , the embodiment 2 of the present invention having anti - experimental depression function can be extrapolated . the influence of embodiment 2 in the resetpine - induced mouse body temperature decrease experiment 4 . 1 experimental animals : icr mice , male , 22 . 0 ± 2 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . 4 . 2 experiment pharmaceuticals : the pharmaceutical of embodiment 2 is provided by beijing wonner biotech . ltd . co ., paroxetine ( paxil ) is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd ., and resetpine is the product of guangdong bangmin pharmaceutical co ., ltd . 4 . 4 dose designs : 1 . high dose of embodiment 2 ( 80 mg / kg / d ); 2 . middle dose of embodiment 2 ( 40 mg / kg / d ); and 3 . low dose of embodiment 2 ( 20 mg / kg / d ). 4 . 5 . 1 group division and administration of drug : the mice are grouped randomly , and 10 mice are in each group . 1 . high dose of embodiment 2 ( 80 mg / kg , p . o ., administered for 7 days ); 2 . middle dose of embodiment 2 ( 40 mg / kg , p . o ., administered for 7 days ); 3 . low dose of embodiment 2 ( 20 mg / kg , p . o ., administered for 7 days ); 4 . paroxetine ( 3 mg / kg , p . o ., administered for 7 days ); and 5 . physiological saline ( p . o .). 4 . 5 . 2 experimental method : after 1 hour of the last administration of drug on the eighth day , the mouse &# 39 ; s anal temperature is determined . then 2 mg resetpine per kilogram of the body weight is given by intraperitoneal injection . after 4 hours of injecting resetpine , the mouse &# 39 ; s anal temperature is determined once again . the depth and time of injecting the thermometer to the mouse &# 39 ; s anus are identical in each temperature measurement . 4 . 5 . 3 statistic calculation : the experimental data are represented as x ± sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . conclusion : according to the above experiment , it can be found that the middle dose of embodiment 2 of the present invention and paroxetine all decrease the reduced body temperature induced by resetpine ; it means that the anti - experimental depression functions of the pharmaceuticals might be related to their effects on the contents of monoamine neurotransmitter . therefore , the embodiment 2 of the present invention having anti - experimental depression function can be extrapolated . 5 . 1 experimental animals : icr mice , male , 22 . 0 ± 2 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . 5 . 2 experiment pharmaceuticals : the pharmaceutical of embodiment 3 is provided by beijing wonner biotech . ltd . co ., and paroxetine ( paxil ) is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd . 5 . 4 dose designs : 1 . high dose of embodiment 3 ( 80 mg / kg / d ); 2 . middle dose of embodiment 3 ( 40 mg / kg / d ); and 3 . low dose of embodiment 3 ( 20 mg / kg / d ). 5 . 5 . 1 group division and administration of drug : the mice are grouped randomly , and 10 mice are in each group . 1 . high dose of embodiment 3 ( 80 mg / kg , p . o ., administered for 7 days ); 2 . middle dose of embodiment 3 ( 40 mg / kg , p . o ., administered for 7 days ); 3 . low dose of embodiment 3 ( 20 mg / kg , p . o ., administered for 7 days ); 4 . paroxetine ( 3 mg / kg , p . o ., administered for 7 days ); and 5 . physiological saline ( p . o .). after 1 hour of the last administration of drug , the mouse tail - hanging experiment is proceeded . 5 . 5 . 2 experimental method : the mouse &# 39 ; s tail ( 1 cm to the tail end ) is taped on the wood strip higher than the platform for 5 cm and hung up for 6 minutes . the time of non - movement of the mouse for the last 5 minutes is recorded . 5 . 5 . 3 statistic calculation : the experimental data are represented as x + sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . conclusion : according to the above experiment , it can be found that the high and middle doses of embodiment 3 of the present invention and paroxetine can all decrease the time of non - movement after the mouse &# 39 ; s tail is hung up , significantly different from the physiological group ( control ). therefore , the embodiment 3 of the present invention having anti - experimental depression function can be extrapolated . the influence of embodiment 3 in the resetpine - induced mouse body temperature decrease experiment 6 . 1 experimental animals : icr mice , male , 22 . 0 ± 2 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . 6 . 2 experiment pharmaceuticals : the pharmaceutical of embodiment 3 is provided by beijing wonner biotech . ltd . co ., paroxetine ( paxil ) is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd ., and resetpine is the product of guangdong bangmin pharmaceutical co ., ltd . 6 . 4 dose designs : 1 . high dose of embodiment 3 ( 80 mg / kg / d ); 2 . middle dose of embodiment 3 ( 40 mg / kg / d ); and 3 . low dose of embodiment 3 ( 20 mg / kg / d ). 6 . 5 . 1 group division and administration of drug : the mice are grouped randomly , and 10 mice are in each group . 1 . high dose of embodiment 3 ( 80 mg / kg , p . o ., administered for 7 days ); 2 . middle dose of embodiment 3 ( 40 mg / kg , p . o ., administered for 7 days ); 3 . low dose of embodiment 3 ( 20 mg / kg , p . o ., administered for 7 days ); 4 . paroxetine ( 3 mg / kg , p . o ., administered for 7 days ); and 5 . physiological saline ( p . o .). 6 . 5 . 2 experimental method : after 1 hour of the last administration of drug on the eighth day , the mouse &# 39 ; s anal temperature is determined . then 2 mg resetpine per kilogram of the body weight is given by intraperitoneal injection . after 4 hours of injecting resetpine , the mouse &# 39 ; s anal temperature is determined once again . the depth and time of injecting the thermometer to the mouse &# 39 ; s anus are identical in each temperature measurement . 6 . 5 . 3 statistic calculation : the experimental data are represented as x ± sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . conclusion : according to the above experiment , it can be found that the high , middle and low doses of embodiment 3 of the present invention and paroxetine can all decrease the reduced body temperature induced by resetpine , and it means that the anti - experimental depression functions of the pharmaceuticals might be related to their effects on the contents of monoamine neurotransmitter . therefore , the embodiment 3 of the present invention having anti - experimental depression function can be extrapolated . the influence of embodiment 4 in the mouse olfactory bulb lesion experiment olfactory bulb lesion model : health wistar male rats , secondary , 330 ± 20 g of body weight , are purchased from beijing vital river experimental animal technology ltd . co . ( the quality certificate number : scxk ( jing ) 2002 - 2003 ). 7 . 2 reagents and pharmaceuticals : the pharmaceutical of embodiment 4 is provided by beijing wormer biotech ltd . co . ( lot : 060313 ), and paroxetine is the product of thong mei tianjin smith kline pharmaceuticals co . ltd . ( lot : 04050011 ). the above pharmaceuticals are prepared with 0 . 5 % of sodium carboxymethylcellulose ( cmc - na ) for feeding into the stomach . benzylpenicillin sodium for injection is the product of north china pharmaceutical huasheng co . ltd . ( lot : s0511204 ), and norepinephrine ( ne ) and 5 - hydrotryptamine ( 5 - ht ) standards are the products of sigma co . other reagents are all marketed . 7 . 3 equipments : self - made open field activity box , step through box , rat stereotaxic instrument , high performance liquid chromatography ( hplc ), and 10 - tube γ radiation immunity arithmometer ( mode : dfm - 96 ). 7 . 4 . 1 group division and administration of drug : the rats are grouped randomly into 6 groups . 1 . false therapy group ; 2 . model group ( control ); 3 . high dose of embodiment 4 ( 60 mg / kg / d ); 4 . middle dose of embodiment 4 ( 30 mg / kg / d ); 5 . low dose of embodiment 4 ( 15 mg / kg / d ); and 6 . paroxetine ( 2 mg / kg / d ). the test drugs and the positive drug are prepared with 0 . 5 % of cmc - na for feeding into the stomach once every day . 7 . 4 . 2 preparation method of model : the rat is anesthetized by chloral hydrate . after anesthesia , the linea median of the rat &# 39 ; s fontanel is carved from 1 cm prior to the anterior fontanel to 1 cm behind the anterior fontanel , and the ossa cranii is exposed . the skull windows having 2 mm of diameter are opened from 8 mm prior to the anterior fontanel and from 2 mm of two sides of the linea median . the specially made electric soldering iron is inserted perpendicularly into the skull for 2 seconds , and the olfactory bulb is destroyed . the hemostatic sponge is filled into the skull windows and the skin is sewn . after the therapy , 40 , 000 unit of benzylpenicillin sodium per kilogram of the body weight is given by intraperitoneal injection for every four days , and the tested pharmaceutical is taken continuously for 24 days . 7 . 5 . 1 open field activity experiment : the open field activity box ( 1 m × 1 m × 0 . 4 m ) is constructed by the light blue plywood and the aluminum alloy frame . the box bottom is separated into 25 grids ( 20 cm × 20 cm for each grid ), the circumference is the peripheral grids ( 16 grids ), and others are the central grids ( 9 grids ). the rat is placed in the center of the central grids , and the rat &# 39 ; s cross - grid number ( the number of crossing into the neighboring gird more than 3 claws ) and rat &# 39 ; s standing number ( two forelimbs leaving the ground for more than 1 cm ) are calculated / observed within 3 minutes . 7 . 5 . 2 passive avoidance experiment ( step - through test ): the step through box is configured by the light chamber and the dark chamber , and a channel is linked between the bright chamber and the dark chamber for mouse entrance and exit . the grille of the dark chamber is connected to the electric shock equipment , and a mobile plate is set there between . if the rat enters into the dark chamber , the rat will be electrically shocked . during training , the rat is placed in the light chamber and is back in the hole for adaptation for 5 minutes . then the plate is removed and the rat is observed for another 5 minutes . the time that the rat enters into for the first time is recorded ( electric - shocking latent period ), and the time thereof is the learning record . after 24 hours , the test is repeated . the plate is removed and the dark chamber is electrified for 5 minutes so as to observe the time that the rat enters into the dark chamber for the first time . this is thereof the memory record . 7 . 6 statistic calculation : the experimental data are represented as x + sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . 7 . 7 . 1 the result of the open field activity experiment : please refer to table 7 . conclusion : the result of experiment 7 shows that the high dose of embodiment 4 can obviously reduce the increase of the rat &# 39 ; s horizontal and vertical movements caused by the olfactory bulb lesion , and the middle dose of embodiment 4 also has obvious improving function on the increase of the vertical movement in the rat olfactory bulb lesion model . in addition , the high and middle doses of embodiment 4 have obvious improving effects on the decreases of the rat study and memory functions caused by the olfactory bulb lesion . the influence of embodiment 4 examined in the rat unpredictable long - term stimulus experiment unpredictable long - term stimulus model : health wistar male rats , secondary , 240 ˜ 270 g of body weight , are purchased from beijing vital river experimental animal technology ltd . co . ( the quality certificate number : sock ( jing ) 2002 - 2003 ). 8 . 2 reagents and pharmaceuticals : the pharmaceutical of embodiment 4 is provided by beijing wonner biotech ltd . co . ( lot : 060313 ), and paroxetine is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd . ( lot : 04050011 ). the above pharmaceuticals are prepared with 0 . 5 % of sodium carboxymethylcellulose ( cmc - na ) for feeding into the stomach . benzylpenicillin sodium for injection is the product of north china pharmaceutical huasheng co . ltd . ( lot : s0511204 ), and norepinephrine ( ne ) and 5 - hydrotryptamine ( 5 - ht ) standards are the products of sigma co . other reagents are all marketed . 8 . 3 equipments : self - made open field activity box , step through box , rat stereotaxic instrument , high performance liquid chromatography ( hplc ), and 10 - tube γ radiation immunity arithmometer ( mode : dfm - 96 ). 8 . 4 . 1 group division and administration of drug : the rats are grouped randomly into 6 groups . 1 . false therapy group ; 2 . model group ( control ); 3 . high dose of embodiment 4 ( 60 mg / kg / d ); 4 . middle dose of embodiment 4 ( 30 mg / kg / d ); 5 . low dose of embodiment 4 ( 15 mg / kg / d ); and 6 . paroxetine ( 2 mg / kg / d ). the test drugs and the positive control drug are prepared with 0 . 5 % of cmc - na for feeding into the stomach once every day . unpredictable long - term stimulus model : the rats in the control group eat and drink normally , and there is no stimulus performed . in other 5 groups , one rat is fed in each cage , and the rat is subject to a 24 - day unpredictable stress / stimulus , including 24 - hour abstinence for 3 times , 24 - hour without drinking for 3 times , 24 - hour wet bedding for 3 times ( 200 ml of water is added in the rat cage ), overnight illumination for 3 times , swimming at 4 ° c . for 5 minutes for 3 times , heating at 45 ° c . in the oven for 5 minutes for 3 times , clipping the rat tail for 1 minute for 3 times , and 30 - minute high - speed horizontal shake for 3 times . one stimulus is performed randomly every day and a total of 24 days . each stimulus cannot be performed continuously . the pharmaceutical is fed into the rat &# 39 ; s stomach once every day for a total of 24 days . 8 . 5 . 3 rat swimming by compulsion : this experiment is proceeded for two days after the last administration of drug . on the first day , the experiment is pre - performed for 15 minutes . the water temperature in the glass tank is 25 ° c ., and the depth of water is 25 cm . after 24 hours , the formal experiment is proceeded . after 1 hour of administration of drug , the rat is placed in the tank , and the time of non - movement of the rat for the last 5 minutes is recorded . 8 . 5 . 4 body weight measurement : the increasing values before and after each animal experiment are compared . 8 . 5 . 5 volume test of drinking sucrose : the sucrose - intake volume of the rats are compared . the rats in each group drink 1 % of the sucrose for 1 hour . the drinking volumes are determined before the stimulus and after 3 weeks of the stimulus . after the rat is in abstinence and water for 14 hours , 1 % of the sucrose is placed in the cage and substituted for the original drinking water . the differences between the bottle weight before and after the rat drinking sucrose for 1 hour are measured and recorded , and the sucrose - drinking volume for each time is calculated . the difference of the sucrose - intake volume for each time is compared . 8 . 5 . 6 hplc - electrochemical test : the amounts of norepinephrine and 5 - hydrotryptamine in the rat cerebral cortex are measured . 8 . 6 statistic calculation : the experimental data are represented as 7 ± sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . 8 . 7 . 1 volume test of drinking sucrose : please refer to table 9 . conclusion : the results of experiment 8 are shown as follows . the middle and low doses of embodiment 4 can obviously improve the decreased sucrose - drinking volume and the decreased body weight in response to the unpredictable long - term stress / stimulus . the high , middle and low doses of embodiment 4 can obviously increase the time of non - movement of the rat swimming by compulsion . the high dose of embodiment 4 can obviously improve the decreased rat horizontal and vertical movements caused by the unpredictable long - term stress / stimulus . the low dose of embodiment 4 also has obviously improved function on the decreased rat vertical movement caused by the unpredictable long - term stress / stimulus . the low dose of embodiment 4 has improved function on the decreased rat learning ability caused by the unpredictable long - term stress / stimulus . the high , middle and low doses of embodiment 4 all can obviously increase ne and 5 - ht contents in the rat cerebral cortex . 9 . 1 experiment pharmaceuticals : the pharmaceutical of embodiment 5 is provided by beijing wonner biotech . ltd . co . ( pilot magnification product ), and paroxetine is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd . ( lot : 05070384 ). above - mentioned pharmaceuticals are prepared with physiological saline for feeding into the stomach . 9 . 2 experimental animals : icr mice , male , 20 . 0 ± 1 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . the quality certificate number of mice is sock ( ding ) 2006 - 2008 . 9 . 4 method : seventy ( 70 ) mice are randomly grouped into 5 groups : normal saline ( ns ) group , paroxetine ( 3 mg / kg / d ), high dose of embodiment 5 ( 80 mg / kg / d ), middle dose of embodiment 5 ( 40 mg / kg / d ), and low dose of embodiment 5 ( 20 mg / kg / d ). the pharmaceuticals are fed into mouse &# 39 ; s stomach once every day . after 1 hour of the last administration of drug on the eighth day , the mouse &# 39 ; s tail ( 1 cm to the tail end ) is taped on the horizontal support in an opened box , and the mouse represents the reversed hung status . the mouse head is away from the bottom of the opened box for about 10 cm , and the mouse is hung up for 6 minutes . the time of non - movement of the mouse for the last 5 minutes is recorded . 9 . 5 statistic calculation : the experimental data are represented as x ± sd , and the experimental result is calculated as one - way anova by spss 11 . 5 statistic software . 9 . 6 experimental result : the result of the time of non - movement in the mouse tail - hanging experiment : please refer to table 15 . conclusion : the research result shows that the high , middle and low doses of embodiment 5 and the clinical effective anti - depression pharmaceutical , paroxetine , all can obviously decrease the accumulative time of non - movement in the mouse tail - hanging experiment . it indicates that embodiment 5 has specific anti - experimental depression function . the influence of embodiment 5 in the mouse swimming by compulsion experiment 10 . 1 experiment pharmaceuticals : the pharmaceutical of embodiment 5 is provided by beijing wonner biotech . ltd . co . ( pilot magnification product ), and paroxetine is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd . ( lot : 05070384 ). above - mentioned pharmaceuticals are prepared with physiological saline for feeding into the stomach . 10 . 2 experimental animals : icr mice , male , 20 . 0 ± 1 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . the quality certificate number of mice is scxk ( jing ) 2006 - 2008 . 10 . 4 experimental method : the mouse group and the administration of drugs are like the mouse tail - hanging experiment . the experiment is proceeded in tested mouse in each group after 1 hour of the administration of drug . the mouse is trained to swim for 15 minutes before the experiment and on the eighth day . after 24 hours , the experiment is performed . the mouse is placed in the glass tank having 10 cm of the water depth , 14 cm of the diameter and at 25 ° c . of the water temperature . the accumulative time of non - movement of the mouse in the water for the last 5 minutes is recorded . 10 . 5 statistic calculation : the experimental data are represented as x + sd , and the experimental result is calculated as one - way anova by spss 11 . 5 statistic software . 10 . 6 experiment result : the result of the mouse swimming by compulsion : please refer to table 16 . conclusion : the research result shows that the high , middle and low doses of embodiment 5 and the clinical effective anti - depression pharmaceutical , paroxetine , can all obviously decrease the accumulative time of non - movement in the mouse swimming by compulsion test . it indicates that the embodiment 5 has specific anti - experimental depression function . nine ( 9 ) kg of the remained ginseng debris , 7 kg of the remained liquorice debris and 0 . 9 kg of the jujuba debris from the embodiments 1 and 4 extraction procedures are collected , dried , pulverized , and mixed well for obtaining the debris mixture containing the trace amount of ginsenoside rg1 and rb1 , glycyrrhizic acid and jujuba camp . the control experiment of examining the influence of the debris in the mouse tail - hanging test is proceeded . 11 . 1 experimental animals : icr mice , male , 22 . 0 ± 2 g of body weight , secondary , are provided by the experimental animal science department of capital medical university , beijing . 11 . 2 experiment pharmaceuticals : the debris mixture is provided by beijing wonner biotech . ltd . co ., and paroxetine ( paxil ) is the product of zhong mei tianjin smith kline pharmaceuticals co . ltd . 11 . 4 dose designs : 1 . high dose of debris mixture ( 160 mg / kg / d ); 2 . middle dose of debris mixture ( 80 mg / kg / d ); and 3 . low dose of debris mixture ( 40 mg / kg / d ). 11 . 5 . 1 group division and administration of drug : the mice are grouped randomly with 10 mice in each group . 1 . high dose of debris mixture ( 160 mg / kg , p . o ., administered for 7 days ); 2 . middle dose of debris mixture ( 80 mg / kg , p . o ., administered for 7 days ); 3 . low dose of debris mixture ( 40 mg / kg , p . o ., administered for 7 days ); 4 . paroxetine ( 3 mg / kg , p . o ., administered for 7 days ); and 5 . physiological saline ( p . o .). after 1 hour of the last administration of drug , the mouse tail - hanging experiment is proceeded . 11 . 5 . 2 experimental method : the mouse &# 39 ; s tail ( near to the tail end for 1 cm ) is taped on the wood strip higher than the platform for 5 cm and hung up for 6 minutes . the time of non - movement of the mouse for the last 5 minutes is recorded . 11 . 5 . 3 statistic calculation : the experimental data are represented as x ± sd , and the experimental result is calculated as anova by spss 11 . 5 statistic software . conclusion : according to the above experiment , it can be found that although the high , middle and low doses of the debris mixture can shorten the time of non - movement of the mouse with tail hanging , these differences are not statistically significant in comparison with the physiological saline group ( control ). therefore , the conclusion that the debris mixture lacks anti - experimental depression function can be extrapolated . the application scopes of the oral pharmaceutical of the present invention for treating depression lie in that : 1 . the described oral pharmaceutical of the present invention for treating depression can include the pharmacologically acceptable additives ; 2 . the described oral pharmaceutical of the present invention for treating depression can be manufactured as the known dosage forms , such as powder , capsule , tablet , etc . ; and 3 . the described oral pharmaceutical of the present invention for treating depression can be manufactured as the health food for treating depression . while the invention has been described in terms of what is presently considered to be the most practical and preferred embodiments , it is to be understood that the invention needs not be limited to the disclosed embodiments . on the contrary , it is intended to cover various modifications and similar arrangements included within the spirit and scope of the appended claims , which are to be accorded with the broadest interpretation so as to encompass all such modifications and similar structures .
oral pharmaceutical compositions or functional foods with a mechanism of multi - target receptor retroaction for treating depression comprising ginseng saponin , glycyrrhizic acid and jujuba camp . experiments demonstrate that as compared with the preferred drug for treating depression paroxetine in the art , the present invention has significant anti - depression efficacy .